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A B S T R A C T
Background: Heart failure (HF) is a complex disease that is under the control of different physiological 
systems. Left ventricular mass (LVM) is a strong predictor of HF. The renin-angiotensin system (RAS) may 
contribute to the pathogenesis of HF and LVM. 
Aims: The aim of this study is to examine the association between RAS genetic variants and HF and 
LVM in the cohort of Polish patients with HF.
Methods: The study included 401 patients with HF. Two-dimensional M-mode echocardiography was 
used to assess LVM. Genomic DNA was extracted from blood, and genotyping of the angiotensin-con-
verting enzyme (ACE) (rs4646994), angiotensinogen (AGT) (rs5051), and angiotensin II receptor type 
1 (AGTR1) (rs5186) polymorphisms was carried out using polymerase chain reaction (PCR).
Results: A significant association was found between HF and the genotypes of G(–6)A AGT, and the 
homozygotes AA of AGT were significantly less common in the HF vs control group. The results of this 
study did not confirm the relationship between AGT, ACE and AT1R genetic variants with LVM in Polish 
patients with HF. 
Conclusions: Our results suggested that AGT polymorphism may play a protective role in the devel-
opment of HF. 
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Heart failure (HF) is a growing global health problem that 
is also responsible for high mortality. The most common 
causes of HF are ischemic heart disease (IHD), hypertension 
(HT), valvular heart disease (VD) or cardiomyopathy [1]. 
However, it is known that the etiology of HF is complex 
and researchers are still looking for factors that influence 
the development and progression of HF.
It is already known that the renin-angiotensin system 
(RAS) plays an important role in the pathophysiology of 
left ventricular (LV) dysfunction, left ventricular hyper-
trophy (LVH), regulation of arterial pressure, cardiovas-
cular diseases, and thus, HF [2]. Angiotensinogen (AGT), 
angiotensin-converting enzyme (ACE) and angiotensin II 
receptor type 1 (AGTR1) are key components of RAS. So 
far, researchers have shown that AGT polymorphisms are 
mainly associated with the development of HT or IH [3, 4], 
while the correlations with HF remain inconsistent [5, 6]. 
However, some studies indicate a correlation between AGT 
gene polymorphism and increased left ventricular mass 
(LVM) [7, 8], and LVH is a strong predictor of HF [9].
The insertion/deletion polymorphism (I/D) of the ACE 
gene is the most extensively studied and has been shown 
to be correlated with HT, IHD and other cardiovascular 
intermediate phenotypes [10–15]. Moreover, ACE has been 
known to have a crucial role in the development of cardiac 
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W H A T ’ S  N E W ?
Heart failure (HF) is a major cause of morbidity and mortality in the world. The renin-angiotensin system (RAS) plays an important 
role in the pathophysiology of HF development and left ventricular dysfunction. Left ventricular mass (LVM) is a major contributor 
to the development of heart failure.  The search for genetic variants that could act as prognostic markers that could be used to 
predict poor outcomes and assist in selecting appropriate therapy is still ongoing. To determine the relationship between the 
key RAS genetic variants: G(–6)A angiotensinogen (AGT), insertion/deletion polymorphism of angiotensin-converting enzyme 
(I/D ACE) or A1166C angiotensin II receptor type 1 (AGTR1), and HF or LVM, we studied 401 Polish patients with HF. Our results 
suggested that AGT polymorphism may play a protective role in the development of HF. 
remodeling by either angiotensin II or aldosterone [16]. 
There are some reports that suggest that this polymor-
phism is associated with increased LVM in normotensive 
and hypertensive patients or in patients with cardiomyopa-
thy [17, 18], although there are studies that do not support 
this correlation [19, 20]. While the genetic determinants 
of LVM in patients with HF have not been so extensively 
studied, the role of the I/D ACE polymorphism in shaping 
LVM is not fully understood. There is no direct reporting 
targeting of genetic predisposition to increase LVM in 
patients with HF, and the role of I/D ACE polymorphism in 
LVM modulation may be significant, and thus, for HF may 
be of pivotal importance. 
The effect of AGTR1 on the regulation of LVM was also 
demonstrated, as it was found to influence the regulation of 
blood volume and stimulate the growth and proliferation of 
heart cells, which causes the development of HF [21]. How-
ever, the results of available studies remain controversial 
and other studies were not able to detect any influence of 
RAS gene polymorphisms on LVM [22, 23]. Although the 
potential role of the RAS system in structure and heart 
disorders is relatively well understood, these molecular 
mechanisms involved in LVM in patients with HF continue 
to be studied. Especially, RAS genetic polymorphisms in-
volved in HF pathophysiology are of particular interest as 
the plausible candidates may play a role in modifying LVM. 
Therefore, the aim of our study was to analyze the 
association between the G(–6)A AGT (rs5051), I/D ACE 
(rs4646994) and A1166C AGTR1 (rs5186) genetic variants 




This study was conducted in accordance with the Decla-
ration of Helsinki and was approved by the local bioethics 
committee at the Pomeranian Medical University (PMU) in 
Szczecin, Poland. Written informed consent was obtained 
from study participants.
This was a case-control study of patients with a di-
agnosis of HF from Department of Cardiac Surgery and 
Cardiology Department of PMU. A total of 401 patients 
(293 men, 108 women) included in the study had symp-
tomatic HF, defined as New York Heart Association (NYHA) 
functional class I–IV. The study group with HF included 
patients with IHD (n = 245; 192 men, 53 women), patients 
with VD (n = 68; 37 men, 31 women), and patients with 
combined disease, IHD and VD (n = 88; 64 men, 24 women). 
Among these HF patients were 195 patients with reduced 
ejection fraction <50% (HF with reduced ejection fraction 
[HfrEF] subgroup). Doppler echocardiography was used to 
examine LV dysfunction.
Demographic data and medical history of patients were 
collected from their medical chart records. The control 
group was consisted of 120 volunteers (43 men, 77 women) 
without history of cardiac disease.
Echocardiography 
Transthoracic echocardiography was performed using an 
Acuson Sequoia 512 unit (Siemens, Munich, Germany) 
equipped with a 2–4 MHz imaging transducer, accord-
ing to the recommendations of the American Society of 
Echocardiography (ASE). Measurements of LV end-dias-
tolic diameter (LVEDD), LV septal wall thickness diameter 
(IVTd) and posterior wall thickness diameter (PWTd) were 
obtained in the M-mode parasternal long-axis view. An 
average of values after three image acquisitions was 
calculated. In cases with suboptimal M-mode acquisition, 
measurements in two-dimensional views were obtained 
instead. LVM was calculated with the ASE-recommended 
formula [24]: LVM (g) = 0.8 × {1.04 [(LVEDD + PWTd + 
IVTd)3 – (LVEDD)3]} + 0.6 g. Body surface area was cal-
culated using the Mosteller formula {square root [height 
(cm) × weight (kg)]/3600} and LVM was indexed to the 
body surface area. LVH was defined as LV mass index (LVMI) 
>115 g/m2 in men and >95 g/m2 in women [24].
Genotyping
Genomic DNA was isolated from whole blood collected into 
ethylenediaminetetraacetic acid tubes using the QIAamp 
Blood DNA Mini Kit (QIAGEN, Hilden, Germany). 
For the analysis, a polymerase chain reaction and 
polymerase chain reaction/restriction fragments length 
polymorphism (PCR/RFLP) method were applied. Geno-
typing of the G(–6)A AGT (rs5051), I/D ACE (rs4646994) and 
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A1166C AGTR1 (rs5186) polymorphisms were carried out 
as previously described [25].
Statistical analysis
The distributions of all quantitative variables, except 
age, were significantly different from normal distribution 
(P <0.05, Shapiro-Wilk’s test). Therefore, quantitative vari-
ables were presented as the median with lower quartile 
and upper quartile, and analyzed using the non-parametric 
Kruskal-Wallis or the Mann-Whitney U test. Qualitative 
variables were presented as number with correspond-
ing percentage and compared between groups with 
the chi-square or the Fisher exact test. Concordance of 
genotype distribution with Hardy-Weinberg equilibrium 
was performed with the exact test. Strength of associa-
tion of qualitative variables with genotypes and alleles 
was described as odds ratio (OR) with 95% confidence 
interval (95% CI). Multivariable logistic regression analysis 
adjusted for age and sex was performed to verify whether 
the associations of genetic polymorphisms with HF are 
independent of these demographic factors. P <0.05 was 
considered statistically significant without correction for 
multiple tests. Bonferroni-corrected P-value thresholds 
were calculated as follows: for the study of associations 
between HF and each of the 3 polymorphisms in 4 models 
of inheritance (dominant, recessive or additive mode for mi-
nor allele as well as comparison of wild-type homozygotes 
with mutated ones), 3 × 4 = 12 tests were performed, so the 
corrected P-value threshold was 0.05/12 = 0.0042; for the 
study of associations between LVMI and each of the 3 pol-
ymorphisms in 4 aforementioned models of inheritance in 
the whole group of HF patients and in the subgroups with 
arterial hypertension or with HFrEF, 3 × 4 × 3 = 36 tests 
were performed, so the corrected P-value threshold was 
0.05/36 = 0.0014. Calculations were performed with Sta-
tistica 13 software (Statistica, Dell Inc. [2016], version 13, 
software.dell.com).
RESULTS
The baseline characteristics of the HF subjects is shown in 
Table 1. The BMI and age proved to be significantly higher 
in the HF group, when compared to controls. Similarly, 
smoking, diabetes, and HT were more common among HF 
patients than controls. Significant differences in all echo-
cardiographic parameters were noted between HF patients 
and controls (higher IVT, PWT, LVM, LVMI, LVEDD and lower 
ejection fraction [EF] values in the HF group) (Table 1).
The G(–6)A AGT, I/D ACE and A1166C AGT1R gene poly-
morphism genotypes were found to be in Hardy-Weinberg 
equilibrium both in the HF and control group (P >0.1). 
We observed a significant association between HF and 
genotypes of G(–6)A AGT (Table 2). Analyses revealed that 
homozygotes AA of AGT are significantly less common in 
the HF group than in the control group (P = 0.014). The neg-
ative association between AA AGT genotype and HF was 
even stronger in multivariable logistic regression model 
adjusted for age and sex (OR, 0.427; 95% CI, 0.245–0.742; 
P = 0.0025), reaching the Bonferroni-corrected P-value 
threshold (<0.0042). No association was found between I/D 
ACE or A1166C AGT1R gene polymorphism and HF, both in 
univariable and multivariable analyses (P >0.3).
The results of association of the G(–6)A AGT, I/D ACE and 
A1166C AGT1R polymorphisms with LVMI in HF patients are 
summarized in Table 3. We did not detect any significant 
correlations. The results of these tests on the effects of G(–6)
A AGT, I/D ACE and A1166C AGT1R polymorphisms with 
LVH defined as LVMI >115 g/m2 in men and >95 g/m2 in 
women are presented in Table 4. We did not find any sig-
nificant correlations.
We also found no relationship between the studied pol-
ymorphisms and LVMI in the subgroup of patients with HF 
and arterial hypertension (n = 309; P >0.1; data not shown). 
Subsequently, we conducted an analysis of the effect of 
G(–6)A AGT, I/D ACE and A1166C AGT1R genotypes on LVH 
in a subgroup of HF patients with HFrEF <50% (Table 5). 
Table 1. Clinical and echocardiographic characteristics of patients with HF and control group
Characteristics HF cases (n = 401) Control (n = 120) P-valuea
Age, years 66.0 (61.0–71.0) 56.0 (49.0–63.0) <0.0001
BMI, kg/m2 29.0 (25.8–31.7) 27.3 (24.8–29.4) <0.0001
Males 293 (73) 77 (64) 0.077
Smoking 126 (31) 24 (20) 0.021
Diabetes mellitus 258 (64) 9 (7) <0.0001
Hypertension 337 (84) 24 (20) <0.0001
Echocardiographic parameters  
IVT, cm 1.25 (1.10–1.40) 0.97 (0.95–1.00) <0.0001
PWT, cm 1.10 (1.00–1.25) 1.05 (1.00–1.10) <0.0001
LVEDD, cm 5.00 (4.61–5.50) 4.75 (4.31–5.05) <0.0001
EF, % 50.0 (40.0–55.0) 64.0 (62.0–67.2) <0.0001
LVM, g 241.8 (195.9–293.8) 171.5 (147.9–190.3) <0.0001
LVMI, g/m2 125.7 (99.3–149.5) 88.8 (76.0–102.5) <0.0001 
Quantitative variables are presented as median (IQR) and qualitative data are presented as a number with corresponding percentage.
aThe Fisher exact test for qualitative variables and the Mann-Whitney U test for quantitative variables.
Abbreviations: BMI, body mass index; EF, ejection fraction; HF, heart failure; IVT, left ventricular septal wall thickness; LVEDD, left ventricular end-diastolic diameter; LVM, left 
ventricular mass; LVMI, left ventricular mass index; PWT, posterior wall thickness
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P-valuea Compared genotypes or 
alleles
OR (95% CI) P-valueb
AGT genotype
GG 108 26.9% 31 25.8% 0.042 AA + GA vs GG 0.945 (0.594–1.504) 0.811
GA 215 53.6% 53 44.2% AA vs GA + GG 0.564 (0.355–0.895) 0.014c
AA 78 19.6%  36 30.0% AA vs GG 0.622 (0.355–1.091) 0.096
AGT allele
G 431 53.7% 115 47.9% — A vs G 0.792 (0.593–1.057) 0.113
A 371 46.3% 125 52.1% —
ACE genotype
II 92 22.9% 27 22.5% 0.99 DD + ID vs II 0.975 (0.599–1.588) 0.919
ID 207 51.6% 62 51.7% DD vs ID + II 0.979 (0.614–1.562) 0.930
DD 77 25.5% 31 25.8% DD vs II 0.966 (0.536–1.738) 0.907
ACE allele
I 391 48.8% 116 48.3% —
D vs I
0.983 (0.737–1.312) 0.909
D 411 51.2% 124 51.7% —
AGTR1 genotype
AA 219 54.6% 61 50.8% 0.73 CC + AC vs AA 0.859 (0.571–1.293) 0.466
AC 154 38.4% 49 40.8% CC vs AC + AA 0.826 (0.389–1.753) 0.618
CC 28 7.0% 10 8.4% CC vs AA 0.780 (0.359–1.694) 0.529
AGTR1 allele
A 592 73.8% 171 71.3% — C vs A 0.879 (0.638–1.212) 0.431
C 210 26.2% 69 28.8% —
aThe Chi-square test for difference in frequencies of 3 genotypes. bThe Chi-square test for difference in frequencies of 2 genotypes, genotype groups or alleles. cOR, 0.427; 
95%CI, 0.245–0.742; P = 0.0025 in multivariable logistic regression model adjusted for age and sex.
Abbreviations: ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AGTR1, angiotensin II receptor type 1; CI, confidence interval; HF, heart failure; I/D, insertion/
deletion; OR, odds ratio
Table 3. Association of G(–6)A AGT, I/D ACE, A1166C AGTR1 genotypes and LVMI in HF patients (n = 401)




AA + GA vs GG 0.953
GA 121.3 (98.3–146.1) AA vs GA + GG 0.126
AA 132.8 (103.2–152.9) AA vs GG 0.315
ACE genotype
 II 126.1 (99.3–150.0)
0.290
DD + ID vs II 0.689
ID 126.1 (101.5–152.8) DD vs ID + II 0.116
DD 118.8 (96.2–141.0) DD vs II 0.233
AGTR1 genotype
AA 121.4 (100.7–145.4) 
0.241
CC + AC vs AA 0.284
AC 132.5 (99.8–155.6) CC vs AC + AA 0.357
CC 116.9 (88.0–142.8) CC vs AA 0.516
LVMI is presented as median (IQR).
aThe Kruskal-Wallis test. bThe Mann-Whitney U test.
Abbreviations: see Table 1 and Table 2
The presence of the DD ACE genotype was significantly 
associated with a lower prevalence of LVH in patients with 
HFrEF (OR, 0.450 [95%CI 0.226–0.895]; P = 0.021). However, 
this association did not reach Bonferroni-corrected  P-value 
threshold (<0.0014).
DISCUSSION
This study evaluated the role of the G(–6)A AGT, I/D ACE 
and A1166C AGTR1 polymorphisms with HF and LVM in 
patients with HF. Although the association between the 
RAS polymorphisms and cardiovascular disease has been 
demonstrated in many previous studies, this relationship is 
still controversial. The importance of RAS polymorphisms in 
relation to HF has not been fully explained and is still widely 
discussed, and reports on these issues are contradictory. To 
our knowledge, this is the first cohort study that examined 
the association of the key RAS gene polymorphisms and 
HF and LVM in Polish patients. The present study demon-
strated a correlation between HF and the AA genotype of 
the AGT gene.
Excessive circulating and tissue angiotensin II and 
aldosterone levels have been shown to lead to a profi-
brotic, proinflammatory, and prohypertrophic milieu that 
causes remodeling and dysfunction in cardiovascular and 
renal tissues [26]. Therefore, molecular variants of RAS are 
considered to be important for LVM, and thus, HF. To date, 
the relationship of M235T AGT polymorphism and HF was 
the most studied. It has been demonstrated that the con-
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Table 4. Association of G(–6)A AGT, I/D ACE, A1166C AGTR1 genotypes and LVH in HF patient group (n = 401) 




P-valuea Compared genotypes 
or alleles
OR (95% CI) P-valueb
AGT genotype
GG 71 27.1% 37 26.6% 0.23 AA + GA vs GG 0.976 (0.613–1.553) 0.918
GA 134 51.6 % 81 58.3% AA vs GA + GG 1.562 (0.902–2.706) 0.109
AA 57 21.8 % 21 15.1% AA vs GG 1.414 (0.747–2.680) 0.287
AGT allele  
G 276 52.7% 155 55.8% — A vs G 1.132 (0.845–1.517) 0.405
A 248 47.3% 123 44.2% —
ACE genotype
II 62 23.7%  30 21.6% 0.28 DD + ID vs II 0.888 (0.542–1.456) 0.637
ID 140 53.5%  67 48.2% DD vs ID + II 0.686 (0.432–1.090) 0.109
DD 60 22.9%  42 30.2% DD vs II 0.828 (0.619–1.109) 0.205
ACE allele
I 264 50.4% 127 45.7% — D vs I 0.828 (0.619–1.109) 0.205
D 260 49.6% 151 54.3% —
AGTR1 genotype
AA 139 53.1% 80 57.6% 0.49 CC + AC vs AA 1.200 (0.793–1.817) 0.389
AC 106 40.5% 48 34.5% CC vs AC + AA 0.807 (0.367–1.775) 0.594
CC 17 6.5% 11 7.9% CC vs AA 0.890 (0.397–1.993) 0.776
AGTR1 allele
A 384 73.2% 70 25.2% — C vs A 1.083 (0.777–1.511) 0.637
C 140 26.7% 208 74.82% —
aThe Chi-square test for difference in frequencies of three genotypes. bThe Chi-square test for difference in frequencies of two genotypes, genotype groups or alleles.
Abbreviations: see Table 1 and Table 2
Table 5. Association of G(–6)A AGT, I/D ACE, A1166C AGTR1 genotypes and LVH in HF patients with reduced ejection fraction (n = 195) 
Polymorphism HFrEF patients  
with LVH (n = 138)
HFrEF patients  
without LVH (n = 57)
P-valuea Compared genotypes 
or alleles
OR (95% CI) P-valueb
AGT genotype
GG 36 26.1% 13 22.8% 0.889 AA + GA vs GG 0.837 (0.405–1.730) 0.631
GA 77 55.8% 33 57.9% AA vs GA + GG 0.925 (0.421–2.034) 0.847
AA 25 18.1% 11 19.3% AA vs GG 0.821 (0.317–2.125) 0.684
AGT allele
G 149 54.0% 59 51.8% — A vs G 0.914 (0.591–1.416) 0.688
A 127 46.0% 55 48.3% —
ACE genotype
II 38 27.5% 11 19.3% 0.063 DD + ID vs II 0.629 (0.295–1.341) 0.228
ID 73 52.9% 26 45.6% DD vs ID + II 0.450 (0.226–0.895) 0.021
DD 27 19.6% 20 35.1% DD vs II 0.391 (0.161–0.948) 0.035
ACE allele
I 149 54.0% 48 42.1% — D vs I 0.620 (0.399–0.963) 0.033
D 127 46.0% 66 57.9% —
AGTR1 genotype
AA 72 52.2% 33 57.9% 0.632 CC + AC vs AA 1.260 (0.676–2.350) 0.466
AC 54 39.1% 21 36.8% CC vs AC + AA 1.714 (0.465–6.320) 0.413
CC 12 8.7% 3 5.3% CC vs AA 1.833 (0.486–9.360) 0.366
AGTR1 allele
A 198 71.7% 87 76.3% — C vs A 1.269 (0.766–2.103) 0.354
C 78 28.3% 27 23.7% —
aThe Chi-square test for difference in frequencies of three genotypes. bThe Chi-square test for difference in frequencies of two genotypes, genotype groups or alleles.
Abbreviations: HFrEF, HF patients with reduced ejection fraction; LVH, left ventricular hypertrophy; other, see Table 1 and Table 2
centration of AGT in blood increases with the number of 
T235 alleles [27]. Some studies demonstrate that this single 
nucleotide polymorphism (SNP) of AGT may be associated 
with HF in different populations [27, 28], whereas some 
studies did not find associations between M235T AGT 
and HF [7, 29]. In our study, we examined the association 
between the G(–6)A AGT polymorphism with HF, and this 
polymorphism remains in very tight linkage disequilibrium 
with T235 AGT and marks the original form of the gene. The 
functionality of (–6G) AGT variants was demonstrated by 
their influence on the basal transcription rate [30]. In this 
study, we found association between G(–6)A of AGT and HF 
in our population, the analysis revealed the protective role 
of the homozygotes AA for HF. Additionally, we noted the 
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lack of association of the I/D ACE and A1166C AGTR1 pol-
ymorphisms. The obtained result of the correlation of (–6) 
AGT polymorphism with HF may result from the different 
concentration of AGT. Given the important role of AGT in 
regulating RAS, it is likely that the AGT polymorphism may 
modulate the risk of developing HF in the Polish popula-
tion. However, these findings still need to be clarified.
The association between RAS polymorphisms and LVH 
has been demonstrated in numerous published studies [31, 
32]. However, the relationship between these polymor-
phisms and LVM and HF is still not fully understood, and 
better understanding of the complexity of RAS should help 
modulate this system and consequently improve quality 
of life. As it is known, in the course of HF during pressure 
overload, there is myocardial remodeling, which leads to 
myocardial hypertrophy, as the result of adaptation to 
mechanical workload demands. However, under patholog-
ical conditions of the onset of HF, myocardial remodeling 
reactions often become maladjusted, leading to myocardial 
decompensation. This phenomenon is associated with 
increased wall stress, insufficient or inappropriate cardio-
myocyte hyperplasia, apoptosis or increased fibrosis [26].
In our study, we did not demonstrate any relationship 
between the RAS genes studied and LVM. 
This relatively weak influence of genetic factors on LVM 
in our patients with HF may be due to a strong influence 
of risk factors of HF. In the Polish population, traditional 
risk factors for cardiovascular diseases (e.g., obesity, HT, 
diabetes mellitus, smoking, etc.) are still widespread, and 
as presented by Favé at al. [33], local environment directly 
influences disease-risk phenotypes and genetic variation, 
including fewer common variants, and can also modulate 
individual responses to environmental challenges. Previ-
ously, we presented a study in which we showed that ACE, 
AT1R and MTHFR gene polymorphisms do not predispose 
to a greater LVM in Polish patients with myocardial infarc-
tion [34].
Furthermore, it should be noted that the patients in 
our program were treated for HF (mainly with ACE inhibi-
tors, angiotensin receptor antagonists, calcium inhibitors, 
etc.), especially with drugs from the group of which RAS 
inhibitors may modulate LVM, which may have affected 
our results. It has been proven in numerous studies that 
the inhibition of the RAS as a result of the use of drugs 
from the group of ACE inhibitors influences the course of 
disease processes [35, 36]. 
Moreover, another study demonstrated a genetic 
influence of antihypertensive treatment and the effect 
of RAS blockers on the regression of LVH [37]. It is known 
that ACE inhibitors are among the basic drugs used in the 
treatment of patients with HF and asymptomatic left ven-
tricular dysfunction, as they prevent disease progression, 
have protective effects of LVH, and reduce mortality and 
the frequency of hospitalization [35]. 
Although RAS is an important contributor to LVM mod-
ulation, the contribution and serious consequences of HT 
should be considered. In our study, we did not observe the 
influence of the studied genes on LVM in patients with HF 
who also had HT. We believe this finding can only confirm 
that proper treatment of HT can protect patients against 
myocardial hypertrophy. Many studies have shown that 
appropriate treatment of the effects of HT is associated with 
the regression of LVH [37, 38]; especially antihypertensive 
treatment with ACE inhibitors in patients with the DD 
genotype of the ACE gene presenting the best response 
to LVH regression [39]. 
The limitation of this study is the relatively small study 
group. Moreover, the etiology of HF in the study group is 
diverse, which may affect the obtained results.
HF is a complex disease and the genetic components 
involved in its development are based on the action of 
many genes. Of particular note is LVH in the course of 
HF, which is the main factor influencing the advance-
ment of the disease process, and the exact mechanism 
of which is still not fully clear. As a result, the search for 
genes that can act as prognostic markers that could be 
used to predict poor outcomes and aid in selecting the 
appropriate therapeutic intervention is still ongoing. 
Further study on this complex system is necessary to 
improve medical therapies for cardiovascular diseases, 
allowing us to more adeptly modulate this system and 
improve clinical outcomes. 
CONCLUSIONS
Our results suggested that polymorphism G(–6)A of the AGT 
gene may play a protective role in the development of HF 
in Polish patients. However, further multi-center studies of 
ethnically diverse populations are needed to confirm this 
finding in the future.
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